07-Jul-2021 - Scailyte AG

Spin-off Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery spin-off of ETH Zurich and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and Scailyte’s AI-driven analytics platform ScaiVision™. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to the LUTHOR™’s unprecedented resolution of single-cell transcriptomes, and the ability of ScaiVision™ to detect complex molecular signatures in biological samples.

The joint workflow will focus on applications within oncology and immunology, such as qualification and stratification of patients for clinical trials, analysis of trial results on deep cellular level or analysis and quality control along the development of cell therapies.

The companies kick-start the outreach to pharmaceutical and diagnostic companies, aiming to set up the first pilot projects in Q3-2021.

“The combination of these unique and innovative tools is great news for everyone! Indeed, thanks to an unprecedented level of information and precision, this platform will contribute to making personalized medicine a reality, and ultimately save more lives.” said Stéphane Barges, Chief Executive Officer at Lexogen.

Andrius Serva, PhD, Director of Corporate Development at Scailyte added: “Scailyte’s success in biomarker discovery and validation is tightly linked to high-quality single-cell input datasets. Our ScaiVision™ platform integrates this data together with clinical patient parameters and identifies accurate molecular biomarkers that are used for disease diagnosis, prognosis, prediction of patient response to a treatment or cell therapy QC. I am delighted about the partnership with Lexogen, which will allow us to offer an end-to-end biomarker discovery workflow to the joint customers in pharmaceutical, diagnostic and CRO industries. Together with Lexogen, we will be able to offer the solution for ultra-sensitive biomarkers to more customers and so bring the benefits of precision medicine to more patients.”

Facts, background information, dossiers
More about Scailyte
  • News

    Using algorithms to track down cancer

    Modern medicine is looking for markers that provide early warning of complex diseases. In its quest to discover these “biomarkers”, the ETH spinoff Scailyte has developed software capable of analysing millions of single cells very efficiently. The search for biomarkers is currently one of t ... more

    Scailyte raises CHF 2.75M in seed funding

    Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirm ... more

    ETH spin-off machine running at full speed

    In 2018, ETH Zurich achieved a new record high for the number of spin-offs founded: a total of 27 founding teams took the plunge into independence. While an average of 13 ETH spin-offs were founded per year from 2000 to 2010, the following decade has seen an average of 24 per year. For Detl ... more

  • Companies

    Scailyte AG

    A new and emerging type of analytical devices are producing rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection but it requires sophisticated and innovative computationa ... more